Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing drug candidates across neuroscience, immunology, and oncology. The company generates no product revenue as of FY2025, operating entirely on capital raises and debt financing while advancing its pipeline toward regulatory approval. Biohaven was separated from its former parent and began operating as an independent public company in 2022, listing under File No. 001-41477. CEO Vlad Coric, M.D. previously led the former parent through the FDA approval and commercial launch of Nurtec ODT (rimegepant) for migraine and zavegepant (Zavzpret). Biohaven's lead pipeline candidate, troriluzole, is being developed for spinocerebellar ataxia (SCA) in adults, with a planned neurological specialty sales force for U.S. commercialization if approved. The company entered a Note Purchase Agreement with Beetlejuice SA LLC, an affiliate of Oberland Capital Management, in April 2025, recording notes payable at fair value of $238.9 million as of December 31, 2025.

Revenue model

Biohaven has no approved products and generates no product revenue as of FY2025. The company is funded through equity issuances and debt, including a Note Purchase Agreement with an affiliate of Oberland Capital Management initially measured at $255.8 million in April 2025. Future revenue, if any, would come from product sales, licensing arrangements, or distribution partnerships upon regulatory approval of pipeline candidates.

Products and services

Lead pipeline candidate: troriluzole, in development for spinocerebellar ataxia (SCA) in adults. The company also references prior involvement in the development of rimegepant (Nurtec ODT) and zavegepant (Zavzpret) through its former parent. Pipeline spans neuroscience, immunology, and oncology therapeutic areas, per the FY2025 10-K.

Customers and end markets

No commercial customers as of FY2025. Target end markets, upon approval, are neurological specialty prescribers and patients with spinocerebellar ataxia in the United States, with potential global expansion via licensing or distribution arrangements.

Value-chain role

Clinical-stage drug developer. Biohaven conducts research and development internally and through partnerships. It intends to build a U.S. neurological specialty sales force for troriluzole commercialization, potentially alongside a larger pharmaceutical partner. International commercialization rights would be handled through distribution or licensing arrangements.

Geographic exposure

Primary commercial focus is the United States, per the FY2025 10-K. Global expansion for troriluzole and other candidates is described as contingent on approval and potential partnerships.

Source: SEC 10-K, filed 2026-03-02

Industry: Pharmaceutical Preparations Peers: Acrivon Therapeutics Inc Anika Therapeutics Inc Arcturus Therapeutics Holdings Inc Stoke Therapeutics Inc Biomea Fusion Inc CONCERT PHARMACEUTICALS, INC. Entrada Therapeutics Inc Lexicon Pharmaceuticals Inc Nurix Therapeutics Inc